TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05182294

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIRVO 2, the new asymmetric nasal cannula
Description: The AIRVO 2 is a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patient through a variety of patient interfaces. This is an FDA-approved 510k device for use in hospitals and nursing homes. During HFNT, oxygen will be passed through a heated humidifier (AIRVO 2, Fisher and Paykel Healthcare) and applied continuously through conventional large-bore binasal symmetric prongs or the new asymmetric prongs cannula device, with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep SaO2 ≥ 90% (Airvo 2, Fisher and Paykel Healthcare). Gas flow temperature will be adjusted based on patient's comfort and range from 34-37 degrees centigrade. After completion of the study, patients will be switched back to oxygen therapy administered by nasal prongs or mask..

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIRVO 2, the new asymmetric nasal cannula
Description: The AIRVO 2 is a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patient through a variety of patient interfaces. This is an FDA-approved 510k device for use in hospitals and nursing homes. During HFNT, oxygen will be passed through a heated humidifier (AIRVO 2, Fisher and Paykel Healthcare) and applied continuously through conventional large-bore binasal symmetric prongs or the new asymmetric prongs cannula device, with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep SaO2 ≥ 90% (Airvo 2, Fisher and Paykel Healthcare). Gas flow temperature will be adjusted based on patient's comfort and range from 34-37 degrees centigrade. After completion of the study, patients will be switched back to oxygen therapy administered by nasal prongs or mask..
Study: NCT06037265

Intervention type: DEVICE
Group type: OTHER
Intervention: PAVmed PortIO™ Intraosseous Infusion System
Description: The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with poor/difficult vascular access. The PortIO device may be inserted into the proximal or distal tibia or the proximal humerus in adults, and provides up to 60 days of intraosseous vascular access for delivery of fluids and medications.
Study: NCT05247515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection with nexpowder
Description: At the end of the EMR procedure, the patient will be randomized. In the treated group, Nexpowder will be sprayed thanks to a catheter inserted through the operating channel of the endoscope.
Study: NCT05093244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeQuent Please ReX
Description: The SeQuent Please ReX is a conventional rapid exchange balloon tip catheter with a drug-coated balloon (DCB). The surface of the SeQuent Please ReX balloon is coated with paclitaxel, embedded in a soluble matrix (resveratrol).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Description: Any commercially available semi-compliant PTCA balloon may be used per the investigator's discretion.
Study: NCT06305923

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: colostrum cream
Description: the intervention in our study is everyday using a cream with active ingridient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Description: using a placebo cream
Study: NCT06375811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elagolix 200 MG
Description: Elagolix tablet

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo or SOC IVF
Description: Sugar pill manufactured to mimic Elagolix 200mg
Study: NCT06477952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Open label Dronabinol treatment for two weeks.
Study: NCT06156176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVIDEx
Description: The COVIDEx intervention was developed by triangulating patient preferences/needs, clinicians' expertise, and best current evidence specific to Long COVID and adapted from interventions for other complex fatigue disorders, which are consistent with evidence informed practice. The program is delivered by trained instructors and comprises of two 50-minute sessions each week for eight weeks. The intervention is designed to be delivered virtually in groups of 6 patients, to eliminate travel requirements for the study. The components of the program are: (i) warm-up (1 min), (ii) cardio training (5 min), (iii) rest (3 min), (iv) balance training (5 min), (v) breathing exercises (3 min), (vi) cognitive training (5 min), (vii) strengthening training (5 min), and (viii) stretching (10min). The COVIDEx program will be paced in order to prevent post-exertional malaise (PEM) in participants.
Study: NCT05932654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSI-045B
Description: Patients will be treated with BSI-045B.
Study: NCT04842149

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bif195 capsules
Description: 1 capsule daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: 1 capsule daily for 8 weeks
Study: NCT05851534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative optimisation program
Description: Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed
Study: NCT05805696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impostor tasks
Description: Tasks to do every week
Study: NCT05810571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative remifentanil consumption
Description: continuous remifentanil infusion will applied for peroperative analgesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: preoperative remifentanil consumption
Description: continuous remifentanil infusion will applied for peroperative analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative remifentanil consumption
Description: continuous remifentanil infusion will applied for peroperative analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postopeartive controlled anlagesia with morphine
Description: postoperative morphine patient controlled analgesia will be applied for postoperative analgesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: postopeartive controlled anlagesia with morphine
Description: postoperative morphine patient controlled analgesia will be applied for postoperative analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postopeartive controlled anlagesia with morphine
Description: postoperative morphine patient controlled analgesia will be applied for postoperative analgesia
Study: NCT06659055

Intervention type: RADIATION
Group type: OTHER
Intervention: DXA Imaging
Description: DXA imaging: lumbar spine, bi-lateral femoral necks

Intervention type: RADIATION
Group type: OTHER
Intervention: DXA Imaging
Description: DXA imaging: lumbar spine, bi-lateral femoral necks

Intervention type: RADIATION
Group type: OTHER
Intervention: EOSedge imaging
Description: Full body or full spine image
Study: NCT06658860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Socket Shield Technique
Description: The modified socket shield technique involves partial retention of the buccal aspect of the tooth root during extraction to preserve the surrounding alveolar bone and soft tissue. This technique is used to optimize the condition for delayed implant placement by preventing resorption of the alveolar ridge.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Tooth Extraction
Description: Conventional tooth extraction involves the complete removal of the tooth without the use of the socket shield technique. This arm served as the control group, with alveolar ridge changes observed and compared with those in the experimental arm over time.
Study: NCT06661824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aggression management care bundle
Description: The aggression management care bundle consists of six components. All of these are high-evidence level interventions consisting of behavioral and nursing interventions aimed at managing aggression. These six interventions are: Risk Assessment, Cognitive Remediation Training, Social Skills Training, De-Escalation Techniques, Milieu Therapy, Improving Sleep.
Study: NCT06660693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Upadacitinib Oral Product
Description: Upadacitinib oral 45mg once daily.
Study: NCT06660043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 40 min circuit training session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: analgesic physical therapy
Description: physical therapy with massage and Transcutaneous Electrical Nerve Stimulation in a 40min session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: analgesic physical therapy AND physical activity
Description: 25 min circuit training session and 15 min physical therapy
Study: NCT06660056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Recurrent or Progressive Gliomas of the Brain
Description: Use of Ommaya capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Recurrent or Progressive Gliomas of the Brain
Description: Use of Ommaya capsules
Study: NCT06660329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Janus Kinase Inhibitor
Description: Tofacitinib is used according to weight: 5\~\<7kg，2mg；7\~\<10kg，2.5mg；10\~\<15kg，3mg；15\~\<25kg，3.5mg；25\~\<40kg，4mg；≥40kg，5mg. All is twice a day.
Study: NCT06658691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary approach
Description: The study investigated a multidisciplinary approach consisting of an endocrinologist, a diabetes specialized nurse, and a clinical pharmacist to assess and improve diabetic foot care by systematic screening, patients' risk categorization, therapy optimization, and tailored education.~Risk of Diabetic Foot Ulcer (DFU) occurrence was assessed and evaluated by the endocrinologist, and the nurse based on the 2019 International Working Group on Diabetes Mellitus (IWGDF). At that point, only the clinical pharmacist knew about patients' allocations.~According to risk stratification, the clinical pharmacist provided intervention patients with educational sessions and tailored materials during scheduled three months follow-up interviews at Jordan University Hospital (JUH) DFU-related clinics.~Moreover, the study evaluated the impacts of the multidisciplinary approach on health-related Quality of Life (QoL) at baseline and at the end of the study. Economic impacts were also further analyzed.
Study: NCT06658782

Intervention type: DIAGNOSTIC_TEST
Intervention: non contrast enhanced MRI
Description: 6 monthly non contrast enhance MRI
Study: NCT06660017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this arm will receive unmedicated syrup solution dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Topical
Description: Patients in this arm will receive ketamine oral rinse dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
Study: NCT05014763

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft
Description: Connective tissue graft surgery will be done for increasing soft tissue volume. In this methods connective tissue will be harvested from lateral palate or tuberosity area.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: connective tissue graft
Description: Connective tissue graft surgery will be done for increasing soft tissue volume. In this methods connective tissue will be harvested from lateral palate or tuberosity area.
Study: NCT06484842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The combined psychological resilience and self-efficacy intervention
Description: Based on the content of the literature analysis and the group's previous research, a joint intervention programme on psychological resilience and self-efficacy for patients undergoing surgery for oesophageal cancer has been developed. The programme consists of 6 sessions in total, including preoperative period and one month after discharge, covering the period when patients' postoperative symptoms occur most severely. The intervention will be conducted in an individual, offline face-to-face format during the patients' hospital stay; considering the smooth implementation of the intervention after the patient will be discharged from the hospital, we will conduct the intervention in an individual, offline face-to-face format during the patient's outpatient review, and set up a WeChat group in case the patients are at home to conduct the intervention in the form of an online punch card.
Study: NCT05911243

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT06484842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The mindfulness intervention
Description: The oesophageal cancer surgery patients in the single intervention group will receive 5 sessions of mindfulness intervention consistent with the mindfulness intervention component of the combined intervention programme. The intervention will be conducted in an individual, offline face-to-face format during the patients' hospitalisation; we will conduct the intervention in an individual, offline face-to-face format during the patients' outpatient review, and set up a WeChat group in case the patients are at home in the form of an online punch card. Each session will include a pre-session reflection and post-session homework. The whole process will be supervised and reminded by interventionists, who will respond to patients' questions in a timely manner to ensure patients safety and the smooth implementation of the intervention. Adjustments and improvements will be made at any time according to the needs of patients undergoing oesophageal cancer surgery.
Study: NCT04655391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib Monohydrate
Description: Given PO
Study: NCT06245395

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: Meta Quest 2 Headset
Study: NCT04655391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib Mesylate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib Fumarate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05911243

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05436067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation app
Description: Delivery of vestibular rehabilitation through an app on a tablet or other portable device. The app takes patients through their rehabilitation session that has been prescribed by a clinician. Exercises are presented in the forms of games that are controlled by head or torso motion via a motion sensor that is placed on that body part. Data on the motion of the patient are calculated from sensor data and sent over the cloud for the clinician to access remotely.
Study: NCT04888559

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast product: Whole grain
Description: This intervention is a whole grain-based breakfast product containing oats and barley.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Breakfast product: Reference
Description: This intervention is a rice-based breakfast product.
Study: NCT04881019

Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: Continuous monitoring of blood sugar over a 10-day period.

Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: Continuous monitoring of blood sugar over a 10-day period.
Study: NCT05911243

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05869734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep health promotion
Description: We will provide sleep hygiene related adjustments in the intervention group A; and brief behavioral treatment for insomnia (BBTI) in the intervention group B.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep health promotion
Description: We will provide sleep hygiene related adjustments in the intervention group A; and brief behavioral treatment for insomnia (BBTI) in the intervention group B.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Urologic health promotion
Description: We will provide information related to urologic health promotion in three groups (2 experimental groups and 1 comparison group).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urologic health promotion
Description: We will provide information related to urologic health promotion in three groups (2 experimental groups and 1 comparison group).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urologic health promotion
Description: We will provide information related to urologic health promotion in three groups (2 experimental groups and 1 comparison group).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pelvic floor muscle training
Description: We will provide information related to pelvic floor muscle training in three groups (2 experimental groups and 1 comparison group).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: We will provide information related to pelvic floor muscle training in three groups (2 experimental groups and 1 comparison group).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: We will provide information related to pelvic floor muscle training in three groups (2 experimental groups and 1 comparison group).
Study: NCT05948813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591
Description: The dose of TY-9591 tablet is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
Study: NCT06131034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Participant in the intervention group will receive music interventions perioperatively.
Study: NCT04658498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedure: Usual Care (UC)
Description: Intermittent spontaneous breathing periods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedure: UC + HI-IMT
Description: UC + Supervised daily sessions of training including 4 sets of 6-10 full vital capacity breaths against an external load using a tapered flow resistive device (POWERbreathe KH2, HaB International, UK). The maximum tolerable resistance allowing patients to inhale at least 70% of their inspiratory vital capacity will be chosen and progressively increased throughout the training period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedure: UC + LI-IMT (sham IMT)
Description: UC + superrvised daily sessions of training including 4 sets of 6-10 breaths at the lowest external imposable load with the tapered flow resistive device (POWERbreathe KH2, HaB International, UK) (i.e. 3 cmH2O).
Study: NCT06375694

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Herbiotics Oral + Ent Probiotic
Description: Chewable Tablets containing Lactobacillus species.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Honest Placebo Pills by Zeebo
Study: NCT06661213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapinarof
Description: A thin layer of tapinarof cream is applied to affected areas once daily.
Study: NCT06660706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-domain intervention
Description: Each session comprises of 45 minutes physical fitness activities targeting on muscle strength, balance, and flexibility; 1-hour cognitive training primarily on reasoning and memory exercises; and 15-minute for nutritional advices based on national diet guidelines for older adults
Study: NCT06661083

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EGCG, FA, HA, B12
Description: EGCG + FA + HA + B12 (1 cps /die)